Pain Associated With Continuous Intravenous Infusion of Bumetanide: A Case Series

Author(s): Lori B. Herges, PharmD, BCPS, Jacob C. Jentzer, MD, Diane D. Brighton, RN, Joseph R. Herges, PharmD, BCPS Narith N. Ou, PharmD, BCPS

Contact Hours 1.00

CERP A 1.00

Expires Apr 01, 2023

Topics: Medication Management, Pain Management

Population: Adult

Role: Staff, Educator

Member: Free
NonMember: $10.00

Added to Collection

Activity Summary

Required reading for all learners: Implicit Bias impacts patient outcomes

Adverse drug events affect patient morbidity and mortality, leading to significant health care costs. Bumetanide is associated with the development of musculoskeletal pain when administered as a continuous infusion. This article describes a case series of patients in a Cardiovascular ICU and Progressive Care Unit who experienced this adverse event.


  • Review the incidence of musculoskeletal pain induced by continuous infusion bumetanide based in the case series and previous literature.
  • Describe the presentation of the adverse effect including time to onset and symptom characteristics.
  • Develop strategies to intervene when the adverse effect of continuous intravenous infusion of bumetanide is suspected.

Continuing Education Disclosure Statement

Successful Completion

Learners must attend/view/read the entire activity and complete the associated evaluation to be awarded the contact hours or CERP. No partial credit will be awarded.


This activity has been reviewed by the Nurse Planner. It has been determined that the material presented here shows no bias. No conflicts of interest have been identified for any individual with the ability to influence the content of this activity. Accreditation refers to recognition of continuing education only and does not imply AACN or ANCC approval or endorsement of any commercial products discussed or displayed in conjunction with this educational activity.


The American Association of Critical-Care Nurses (AACN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's (ANCC's) Commission on Accreditation, ANCC Provider Number 0012. AACN has been approved as a provider of continuing education in nursing by the California State Board of Nursing (CBRN), California Provider number CEP 1036. This activity is approved for 1.00 contact hours.

AACN programming meets the standards for most states that require mandatory continuing education contact hours for license and/or certification renewal. AACN recommends consulting with your state board of nursing or credentialing organization before submitting CE to fulfill continuing education requirements.

Refund Policy

Continuing Education Activities are nonrefundable.